Cargando…
Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
OBJECTIVES: Type 2 diabetes (T2D) is driven by progressive dysfunction and loss of pancreatic β‐cell mass. Imeglimin is a first‐in‐class novel drug candidate that improves glycaemia and glucose‐stimulated insulin secretion in preclinical models and patients. Given evidence that imeglimin can attenua...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029531/ https://www.ncbi.nlm.nih.gov/pubmed/33855202 http://dx.doi.org/10.1002/edm2.193 |